Alliancebernstein L.P. Has $21.88 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Alliancebernstein L.P. trimmed its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 17.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 179,908 shares of the biotechnology company's stock after selling 39,102 shares during the quarter. Alliancebernstein L.P. owned 0.19% of Sarepta Therapeutics worth $21,875,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Manchester Capital Management LLC boosted its holdings in Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 110 shares in the last quarter. MassMutual Private Wealth & Trust FSB boosted its stake in Sarepta Therapeutics by 169.6% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock valued at $30,000 after buying an additional 156 shares in the last quarter. Sunbelt Securities Inc. grew its position in Sarepta Therapeutics by 446.2% in the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 232 shares during the period. Newbridge Financial Services Group Inc. acquired a new position in Sarepta Therapeutics during the fourth quarter worth $36,000. Finally, Steward Partners Investment Advisory LLC lifted its holdings in shares of Sarepta Therapeutics by 164.4% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock valued at $38,000 after acquiring an additional 194 shares during the period. 86.68% of the stock is owned by institutional investors.

Remove Ads

Insiders Place Their Bets

In other news, Director Claude Nicaise sold 2,491 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the transaction, the director now owns 27,812 shares in the company, valued at $2,771,187.68. This represents a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 7.70% of the company's stock.

Analysts Set New Price Targets

SRPT has been the subject of a number of recent analyst reports. Scotiabank dropped their target price on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating for the company in a research report on Thursday, March 20th. Needham & Company LLC dropped their price objective on shares of Sarepta Therapeutics from $202.00 to $183.00 and set a "buy" rating for the company in a report on Thursday, April 3rd. Wells Fargo & Company started coverage on Sarepta Therapeutics in a report on Friday. They issued an "overweight" rating and a $115.00 target price on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $163.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. Finally, HC Wainwright raised Sarepta Therapeutics from a "sell" rating to a "neutral" rating and set a $75.00 price objective on the stock in a research note on Wednesday, April 2nd. Six research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Sarepta Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $161.83.

Sarepta Therapeutics Trading Up 1.4 %

Shares of SRPT stock traded up $0.72 on Friday, hitting $51.03. The stock had a trading volume of 4,036,516 shares, compared to its average volume of 1,385,946. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a twelve month low of $48.01 and a twelve month high of $173.25. The company has a fifty day moving average price of $88.11 and a two-hundred day moving average price of $110.20. The firm has a market cap of $4.95 billion, a P/E ratio of 40.82 and a beta of 0.93.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.